FOR IMMEDIATE RELEASE

Doseology Uplists to OTCQB as DOSEF, Expanding U.S. Investor Access to the Emerging Oral Stimulant Pouch Category

Kelowna, British Columbia – March 11, 2026 – Doseology Sciences Inc. (CSE: **MOOD** | OTCQB: **DOSEF** | FSE: **VU70**) ("**Doseology**" or the "**Company**") a consumer product innovation company focused on oral stimulant pouch technologies, is pleased to announce that its common shares have commenced trading on the OTCQB® Venture Market in the United States under the symbol DOSEF.

"We are pleased to expand trading access for U.S. investors through the OTCQB market," said Chris Jackson, Chief Executive Officer of Doseology Sciences Inc. "The United States represents both the largest capital market and one of the most important consumer markets for modern oral stimulant products, and this milestone supports our long-term growth strategy. Trading on OTCQB aligns the Company with higher standards of financial reporting and disclosure, providing greater transparency and confidence for investors as we execute our long-term growth strategy."

The OTCQB is designed for developing and growth-stage public companies that meet higher transparency and governance standards. The OTCQB Venture Market provides investors with greater comfort because companies must maintain current financial reporting, management certification, and ongoing compliance standards.

Further to the company's commitment to adhering to transparency and required reporting for our new listing we have recently announced the appointment of Larry Latowsky as Executive Chairman of the Board of Directors. Mr. Latowsky's years of experience on public and private boards with specialized experiences and knowledge will support our compliance with new markets.

Industry Context

The oral pouch category has emerged as one of the fastest-growing segments within the broader stimulant and nicotine markets, as consumers increasingly shift toward smoke-free and discreet delivery formats. Global companies including Philip Morris International and British American Tobacco have made significant investments in modern oral products as demand for alternative delivery formats continues to expand.

The global energy drink market represents a multi-billion-dollar consumer category, with increasing innovation focused on new delivery formats beyond traditional beverages. Oral pouch technologies are emerging as a potential complementary format for delivering controlled-dose stimulant products in a convenient and portable form.

Strategic Positioning

Doseology is positioning itself as one of the early pure-play public companies focused on the emerging oral stimulant pouch category, combining consumer product development and direct-to-consumer distribution strategies.

The Company is also exploring the development of proprietary stimulant technologies and intellectual property, including next-generation caffeine analog and nicotine-alternative compounds designed for modern oral delivery formats.

As consumer demand evolves toward portable, controlled-dose stimulant delivery formats, Doseology believes oral stimulant pouches may represent a new product segment within the broader global energy and functional stimulant market.

Platform Strategy

Doseology is pursuing a platform approach to oral stimulant innovation, combining product development, brand creation, and digital distribution to launch multiple consumer-facing stimulant products designed for modern lifestyles.

Through its growing brand portfolio and direct-to-consumer platforms, including Doseology's recently acquired retail brand Feed That Brain, the Company aims to build a scalable ecosystem of functional stimulant products within the emerging oral delivery category.

The Company announces that, further to its news release of August 27, 2025 that announced the closing of the acquisition of the "*Feed That Brain*" division operated by Joseph Mimran & Associates Inc. (the "**Vendor**"), it has issued an aggregate of 75,000 pre-funded warrants (the "**Pre-Funded Warrants**") to the Vendor, based upon a deemed price of $1.00 per Pre-funded Warrant. Additional issuances of $75,000 of Pre-Funded Warrants are due on the one (1) year and eighteen (18) month anniversaries of the closing the acquisition in accordance with the asset purchase and sale agreement executed between the parties. The Pre-Funded Warrants are subject to a four-month hold period in accordance with applicable securities laws, which will expire on July 11, 2026.

About Doseology Sciences Inc. (CSE: **MOOD** | OTCQB: **DOSEF** | FSE: **VU70**)

Doseology Sciences Inc. specializes in pouch-based oral stimulant and cognitive support products. The rapidly expanding oral stimulant pouch sector is gaining momentum as consumers seek modern, discreet alternatives to traditional delivery formats. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapor-free, providing an alternative delivery method without inhalation.

From a market perspective, the oral pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability, and format innovation. The pouch sector represents one of the most dynamic and high-growth areas in modern functional consumer products.

For more information visit:

Corporate: www.doseology.com
Shop: www.feedthatbrain.com

On behalf of the Board of Directors,
Chris Jackson
CEO, Director
Doseology Sciences Inc.

Investor & Media Contact:
Email: hello@doseology.com
Phone: 604.908.3095

Forward Looking Statements

This press release contains statements that constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking information is often identified by the words "may," "would," "could," "should," "will," "intend," "plan," "anticipate," "believe," "estimate," "expect" or similar expressions. Readers are cautioned that forward-looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning the business of the Company's future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company's prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law. For more information, investors should review the Company's filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release.